In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this episode unpacks what pharma companies need to know about preparing for an uncertain policy landscape through strategic scenario planning.

Useful resources referenced in this episode:  

You can download the article 'Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future' here. 

Details of the CELforPharma course 'Understanding Pharma Market Access in the US' are available on the CELforPharma website here. 

Send us a text